LifeStance Therapists & Psychiatrists Brentwood
9020 Overlook Boulevard, Suite 130, Brentwood
4.4(253 Google reviews)
United States
5 listed treatment centers serving Brentwood and the surrounding area.
9020 Overlook Boulevard, Suite 130, Brentwood
4.4(253 Google reviews)
9020 Overlook Boulevard, Suite 130, Brentwood
4.9(57 Google reviews)
9020 Overlook Boulevard, Suite 130, Brentwood
4.6(33 Google reviews)
For people in Brentwood considering SPRAVATO®, the cost depends on insurance benefits, the treatment setting, and the prescribed schedule. Ask for an estimate that separates the medication from the supervised treatment and monitoring visit: both may be billed. An estimate is not a guarantee of what your insurer will pay.
Prior authorization is common. Your insurer may request records of earlier antidepressant trials, including which medicines you took and how you responded. Ask the treatment center which records it needs, who submits the authorization request, and whether approval is required before scheduling. Also ask when authorization may need renewal.
Medicare coverage may fall under Part B or Part D depending on the plan and setting. Tennessee Medicaid coverage also depends on the plan and treatment setting. Neither program guarantees payment for every patient or at every center; confirm benefits and whether the center can bill your coverage directly.
Manufacturer savings programs exist for eligible commercially insured patients, but not for patients using government insurance. Eligibility rules apply, and assistance may not cover every visit-related charge. Ask for current program terms rather than assuming you qualify.
Before starting, ask the center and insurer:
There is no treatment center currently listed in Brentwood in this directory. The available directory information also provides no other Tennessee cities with listed centers to suggest. This is a directory limitation, not proof that treatment is unavailable. Ask your prescribing clinician or insurer for help locating a SPRAVATO® REMS-certified healthcare setting, then confirm certification directly with the center before arranging care.
Spravato is not a take-home medication. You administer the nasal spray yourself at the certified setting under a healthcare provider’s direct observation. Monitoring continues for at least two hours after each dose. Allow additional time for check-in, preparation, and assessment before leaving; do not plan around an exact two-hour appointment.
The typical labeled schedule starts with twice-weekly treatment during weeks 1–4, followed by weekly visits during weeks 5–8. Maintenance may be weekly or every two weeks. Your prescriber individualizes the schedule, so confirm your actual visit plan before making ongoing arrangements.
Arrange for someone else to drive you home after every visit. You must not drive or operate machinery until the next day after a restful sleep. Ask the center about its transportation and discharge requirements before relying on any ride service. A backup ride can help prevent last-minute disruptions.
When planning time away from work, account for the appointment, travel, and driving restrictions afterward. Discuss scheduling options with the center, especially if your job involves driving or machinery. Consider arranging help with childcare or other responsibilities on treatment days, and ask what to do if transportation problems threaten a scheduled visit.
This directory currently has no listed SPRAVATO® treatment center in Brentwood and no other listed Tennessee cities to recommend. Ask your clinician or insurer for help finding a REMS-certified setting. Before booking, confirm the center’s certification, whether it is accepting patients, and whether it can evaluate your condition. Offering treatment alone does not establish that a location is certified.
Spravato is FDA-approved for adults with treatment-resistant depression, either alone or with an oral antidepressant. It is also approved, with an oral antidepressant, for depressive symptoms in adults with major depressive disorder and acute suicidal thoughts or behavior. It is not approved for children. A clinician must review your diagnosis, treatment history, and safety considerations; an approved indication does not guarantee that it is appropriate for you.
Coverage depends on your plan and treatment setting. Prior authorization and documentation of earlier antidepressant trials are common requirements. Ask about coverage for both the medication and the monitored visit, along with network status and your share of costs. Medicare and Tennessee Medicaid may cover treatment depending on the plan and setting, but you should confirm benefits before starting.
You self-administer the nasal spray under direct observation at a REMS-certified healthcare setting. Staff monitor you for at least two hours after the dose, including for sedation, dissociation, breathing problems, and blood pressure increases. The visit may take longer once preparation and assessment are included. You cannot take the medication home, and someone else must drive you home afterward.
Discuss sedation, dissociation—a feeling of disconnection—respiratory depression, and blood pressure increases with your clinician. Spravato carries boxed warnings for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors. It is a Schedule III controlled substance. Share your health history and medications so your clinician can assess risks, and report concerning symptoms during monitoring rather than waiting until you leave.
No. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behavior, and it does not replace hospitalization when clinically needed. Do not wait for an appointment or insurance approval during a crisis. Call or text 988 for crisis support, or call 911 in an emergency. Its approved use for depressive symptoms with acute suicidal thoughts or behavior requires an oral antidepressant.
Approved uses, nearby treatment centers, and medically sourced patient guides.